Ginkgolic acid regulates myogenic development by influencing the proliferation and differentiation of C2C12 myoblast cells

Liu,Hyunju; Joung,Hosouk

doi:10.3892/mmr.2024.13328

Ginkgolic acid regulates myogenic development by influencing the proliferation and differentiation of C2C12 myoblast cells

Authors:
- Hyunju Liu
- Hosouk Joung
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Chosun University College of Medicine, Gwangju 61452, Republic of Korea, Research Institute of Medical Sciences, Chonnam National University Medical School, Hwasun‑gun, Jeollanam‑do 58128, Republic of Korea
Published online on: September 10, 2024 https://doi.org/10.3892/mmr.2024.13328
Article Number: 204
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ginkgolic acid (GA), isolated from the leaves and seed coats of Ginkgo biloba, exerts several biological effects, including antitumor, antibacterial, anti‑HIV and anti‑inflammatory effects. However, the effects of GA on C2C12 myoblasts remain unclear. The present study assessed cell viability with the MTT assay and evaluated colony formation through crystal violet staining. Flow cytometry was used to analyze apoptosis with Annexin V/7‑AAD staining, proliferation with Ki67 staining and cell cycle arrest. Western blotting detected myogenic markers and other relevant proteins. Myotube formation was examined by immunofluorescence, and autophagy was measured using an LC3 antibody‑based kit via flow cytometry. The present study showed that treatment of C2C12 cells with GA significantly inhibited their viability and colony formation capacity but did not trigger apoptosis, as indicated by Annexin V/7‑AAD staining. However, Ki67 staining indicates that GA exerted dose‑dependent antiproliferative effects. Further analysis revealed that GA partially inhibited the growth of C2C12 cells via cell cycle arrest in S phase, highlighting its role in the disruption of cell proliferation. Furthermore, treatment with GA impaired myoblast differentiation, as evidenced by a reduction in the expression of the myogenesis markers, the myosin‑heavy chain, myoblast determination protein 1 and myogenin, and suppressed myotube formation. Notably, during C2C12 cell differentiation, GA promoted apoptosis without affecting cell cycle progression or Ki67 expression. Mechanistically, GA could suppress nuclear extracellular signal‑regulated kinase phosphorylation, suggesting that it modulates cell proliferation pathways. Moreover, GA triggered autophagy in differentiated C2C12 cells, as confirmed by elevated LC3 II levels. These findings highlight the multifaceted effects of GA on C2C12 cells.

View Figures

View References

1	Tajbakhsh S: Skeletal muscle stem cells in developmental versus regenerative myogenesis. J Intern Med. 266:372–389. 2009. View Article : Google Scholar : PubMed/NCBI
2	Burattini S, Ferri P, Battistelli M, Curci R, Luchetti F and Falcieri E: C2C12 murine myoblasts as a model of skeletal muscle development: Morpho-functional characterization. Eur J Histochem. 48:223–233. 2004.PubMed/NCBI
3	Lyu P and Jiang H: RNA-sequencing reveals upregulation and a beneficial role of autophagy in myoblast differentiation and fusion. Cells. 11:35482022. View Article : Google Scholar
4	Cao RY, Li J, Dai Q, Li Q and Yang J: Muscle atrophy: Present and future. Adv Exp Med Biol. 1088:605–624. 2018. View Article : Google Scholar : PubMed/NCBI
5	Yang J, Cao RY, Li Q and Zhu F: Muscle atrophy in cancer. Adv Exp Med Biol. 1088:329–346. 2018. View Article : Google Scholar : PubMed/NCBI
6	Cao YY, Wang Z, Yu T, Zhang Y, Wang ZH, Lu ZM, Lu WH and Yu JB: Sepsis induces muscle atrophy by inhibiting proliferation and promoting apoptosis via PLK1-AKT signalling. J Cell Mol Med. 25:9724–9739. 2021. View Article : Google Scholar : PubMed/NCBI
7	Sandri M: Protein breakdown in muscle wasting: Role of autophagy-lysosome and ubiquitin-proteasome. Int J Biochem Cell Biol. 45:2121–2129. 2013. View Article : Google Scholar : PubMed/NCBI
8	Bodine SC and Baehr LM: Skeletal muscle atrophy and the E3 ubiquitin ligases MuRF1 and MAFbx/atrogin-1. Am J Physiol Endocrinol Metab. 307:E469–E484. 2014. View Article : Google Scholar : PubMed/NCBI
9	Schuelke M, Wagner KR, Stolz LE, Hübner C, Riebel T, Kömen W, Braun T, Tobin JF and Lee SJ: Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med. 350:2682–2688. 2004. View Article : Google Scholar : PubMed/NCBI
10	Zarrabi A, Perrin D, Kavoosi M, Sommer M, Sezen S, Mehrbod P, Bhushan B, Machaj F, Rosik J, Kawalec P, et al: Rhabdomyosarcoma: Current therapy, challenges, and future approaches to treatment strategies. Cancers (Basel). 15:52692023. View Article : Google Scholar : PubMed/NCBI
11	Ndjoko K, Wolfender JL and Hostettmann K: Determination of trace amounts of ginkgolic acids in Ginkgo biloba L. leaf extracts and phytopharmaceuticals by liquid chromatography-electrospray mass spectrometry. J Chromatogr B Biomed Sci Appl. 744:249–255. 2000. View Article : Google Scholar : PubMed/NCBI
12	Zhou C, Li X, Du W, Feng Y, Kong X, Li Y, Xiao L and Zhang P: Antitumor effects of ginkgolic acid in human cancer cell occur via cell cycle arrest and decrease the Bcl-2/Bax ratio to induce apoptosis. Chemotherapy. 56:393–402. 2010. View Article : Google Scholar : PubMed/NCBI
13	Lü JM, Yan S, Jamaluddin S, Weakley SM, Liang Z, Siwak EB, Yao Q and Chen C: Ginkgolic acid inhibits HIV protease activity and HIV infection in vitro. Med Sci Monit. 18:BR293–BR298. 2012. View Article : Google Scholar : PubMed/NCBI
14	Hua Z, Wu C, Fan G, Tang Z and Cao F: The antibacterial activity and mechanism of ginkgolic acid C15:1. BMC Biotechnol. 17:52017. View Article : Google Scholar : PubMed/NCBI
15	Li J, Li A, Li M, Liu Y, Zhao W and Gao D: Ginkgolic acid exerts an anti-inflammatory effect in human umbilical vein endothelial cells induced by ox-LDL. Pharmazie. 73:408–412. 2018.PubMed/NCBI
16	Ma J, Duan W, Han S, Lei J, Xu Q, Chen X, Jiang Z, Nan L, Li J, Chen K, et al: Ginkgolic acid suppresses the development of pancreatic cancer by inhibiting pathways driving lipogenesis. Oncotarget. 6:20993–21003. 2015. View Article : Google Scholar : PubMed/NCBI
17	Qiao L, Zheng J, Jin X, Wei G, Wang G, Sun X and Li X: Ginkgolic acid inhibits the invasiveness of colon cancer cells through AMPK activation. Oncol Lett. 14:5831–5838. 2017.PubMed/NCBI
18	Baek SH, Ko JH, Lee JH, Kim C, Lee H, Nam D, Lee J, Lee SG, Yang WM, Um JY, et al: Ginkgolic acid inhibits invasion and migration and TGF-β-induced EMT of lung cancer cells through PI3K/Akt/mTOR inactivation. J Cell Physiol. 232:346–354. 2017. View Article : Google Scholar : PubMed/NCBI
19	Hamdoun S and Efferth T: Ginkgolic acids inhibit migration in breast cancer cells by inhibition of NEMO sumoylation and NF-κB activity. Oncotarget. 8:35103–35115. 2017. View Article : Google Scholar : PubMed/NCBI
20	Liu D, Li Z, Yang Z, Ma J and Mai S: Ginkgoic acid impedes gastric cancer cell proliferation, migration and EMT through inhibiting the SUMOylation of IGF-1R. Chem Biol Interact. 337:1093942021. View Article : Google Scholar : PubMed/NCBI
21	Fukuda I, Ito A, Hirai G, Nishimura S, Kawasaki H, Saitoh H, Kimura K, Sodeoka M and Yoshida M: Ginkgolic acid inhibits protein SUMOylation by blocking formation of the E1-SUMO intermediate. Chem Biol. 16:133–140. 2009. View Article : Google Scholar : PubMed/NCBI
22	Liu H, Lee SM and Joung H: 2-D08 treatment regulates C2C12 myoblast proliferation and differentiation via the Erk1/2 and proteasome signaling pathways. J Muscle Res Cell Motil. 42:193–202. 2021. View Article : Google Scholar : PubMed/NCBI
23	Miller JB: Myogenic programs of mouse muscle cell lines: Expression of myosin heavy chain isoforms, MyoD1, and myogenin. J Cell Biol. 111:1149–1159. 1990. View Article : Google Scholar : PubMed/NCBI
24	Jones NC, Fedorov YV, Rosenthal RS and Olwin BB: ERK1/2 is required for myoblast proliferation but is dispensable for muscle gene expression and cell fusion. J Cell Physiol. 186:104–115. 2001. View Article : Google Scholar : PubMed/NCBI
25	Aman Y, Schmauck-Medina T, Hansen M, Morimoto RI, Simon AK, Bjedov I, Palikaras K, Simonsen A, Johansen T, Tavernarakis N, et al: Autophagy in healthy aging and disease. Nat Aging. 1:634–650. 2021. View Article : Google Scholar : PubMed/NCBI
26	Yin H, Price F and Rudnicki MA: Satellite cells and the muscle stem cell niche. Physiol Rev. 93:23–67. 2013. View Article : Google Scholar : PubMed/NCBI
27	Zhang W and Liu HT: MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 12:9–18. 2002. View Article : Google Scholar : PubMed/NCBI
28	Cao Y, Kumar RM, Penn BH, Berkes CA, Kooperberg C, Boyer LA, Young RA and Tapscott SJ: Global and gene-specific analyses show distinct roles for Myod and Myog at a common set of promoters. EMBO J. 25:502–511. 2006. View Article : Google Scholar : PubMed/NCBI
29	Andrés V and Walsh K: Myogenin expression, cell cycle withdrawal, and phenotypic differentiation are temporally separable events that precede cell fusion upon myogenesis. J Cell Biol. 132:657–666. 1996. View Article : Google Scholar : PubMed/NCBI
30	Massaccesi L, Goi G, Tringali C, Barassi A, Venerando B and Papini N: Dexamethasone-induced skeletal muscle atrophy increases O-GlcNAcylation in C2C12 cells. J Cell Biochem. 117:1833–1842. 2016. View Article : Google Scholar : PubMed/NCBI
31	Wang LJ, Lu W and Zhou TY: Current applications of dexamethasone for cancer treatment. Yao Xue Xue Bao. 50:1217–1224. 2015.(In Chinese). PubMed/NCBI
32	Madamsetty VS, Mohammadinejad R, Uzieliene I, Nabavi N, Dehshahri A, Garcia-Couce J, Tavakol S, Moghassemi S, Dadashzadeh A, Makvandi P, et al: Dexamethasone: Insights into pharmacological aspects, therapeutic mechanisms, and delivery systems. ACS Biomater Sci Eng. 8:1763–1790. 2022. View Article : Google Scholar : PubMed/NCBI
33	McLoughlin TJ, Smith SM, DeLong AD, Wang H, Unterman TG and Esser KA: FoxO1 induces apoptosis in skeletal myotubes in a DNA-binding-dependent manner. Am J Physiol Cell Physiol. 297:C548–C555. 2009. View Article : Google Scholar : PubMed/NCBI
34	Fernando P, Kelly JF, Balazsi K, Slack RS and Megeney LA: Caspase 3 activity is required for skeletal muscle differentiation. Proc Natl Acad Sci USA. 99:11025–11030. 2002. View Article : Google Scholar : PubMed/NCBI
35	Xia Q, Huang X, Huang J, Zheng Y, March ME, Li J and Wei Y: The role of autophagy in skeletal muscle diseases. Front Physiol. 12:6389832021. View Article : Google Scholar : PubMed/NCBI
36	Tanida I, Wakabayashi M, Kanematsu T, Minematsu-Ikeguchi N, Sou YS, Hirata M, Ueno T and Kominami E: Lysosomal turnover of GABARAP-phospholipid conjugate is activated during differentiation of C2C12 cells to myotubes without inactivation of the mTor kinase-signaling pathway. Autophagy. 2:264–271. 2006. View Article : Google Scholar : PubMed/NCBI
37	McMillan EM and Quadrilatero J: Autophagy is required and protects against apoptosis during myoblast differentiation. Biochem J. 462:267–277. 2014. View Article : Google Scholar : PubMed/NCBI
38	Ding Y, Ding Z, Xu J, Li Y and Chen M: Pharmacological activities of ginkgolic acids in relation to autophagy. Pharmaceuticals (Basel). 15:14692022. View Article : Google Scholar : PubMed/NCBI
39	Yoon SY, Lee JH, Kwon SJ, Kang HJ and Chung SJ: Ginkgolic acid as a dual-targeting inhibitor for protein tyrosine phosphatases relevant to insulin resistance. Bioorg Chem. 81:264–269. 2018. View Article : Google Scholar : PubMed/NCBI
40	Vertegaal ACO: Signalling mechanisms and cellular functions of SUMO. Nat Rev Mol Cell Biol. 23:715–731. 2022. View Article : Google Scholar : PubMed/NCBI
41	Wilkinson KA and Henley JM: Mechanisms, regulation and consequences of protein SUMOylation. Biochem J. 428:133–145. 2010. View Article : Google Scholar : PubMed/NCBI
42	Langston SP, Grossman S, England D, Afroze R, Bence N, Bowman D, Bump N, Chau R, Chuang BC, Claiborne C, et al: Discovery of TAK-981, a first-in-class inhibitor of SUMO-activating enzyme for the treatment of cancer. J Med Chem. 64:2501–2520. 2021. View Article : Google Scholar : PubMed/NCBI
43	Kumar S, Schoonderwoerd MJA, Kroonen JS, de Graaf IJ, Sluijter M, Ruano D, Gonzalez-Prieto R, Verlaan-de Vries M, Rip J, Arens R, et al: Targeting pancreatic cancer by TAK-981: A SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model. Gut. 71:2266–2283. 2022. View Article : Google Scholar : PubMed/NCBI
44	Du L, Liu W, Pichiorri F and Rosen ST: SUMOylation inhibition enhances multiple myeloma sensitivity to lenalidomide. Cancer Gene Ther. 30:567–574. 2023. View Article : Google Scholar : PubMed/NCBI
45	Kim HS, Kim BR, Dao TTP, Kim JM, Kim YJ, Son H, Jo S, Kim D, Kim J, Suh YJ, et al: TAK-981, a SUMOylation inhibitor, suppresses AML growth immune-independently. Blood Adv. 7:3155–3168. 2023. View Article : Google Scholar : PubMed/NCBI